Bermingham Nessan 4

What Happened

• Nessan Bermingham (listed in the filing as "Bermingham Nessan"), a director of Korro Bio, was granted a derivative equity award of 14,677 shares on 2026-06-10. The reported acquisition price is $0.00, so no cash was paid at grant and the reported total value for the transaction is $0.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-11 (timely filing).
• Amount granted: 14,677 shares; reported price: $0.00; total reported cash value: $0.
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director.
• Transaction type: Award/Grant (derivative); code A on Form 4.

Context

• This was an equity award to a non-employee director rather than an open-market purchase or sale. The award vests upon continued service and/or the next annual meeting (per footnote), so the shares are not immediately tradable unless separate terms apply.
• Such director awards are a common form of board compensation and do not by themselves indicate insider buying or selling intent.